---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-045834"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2023-06-02T23:59:59+00:00"
generated_at: "2026-06-14T08:26:23.031679+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics receives FDA guidance for briquilimab in CSU; IND filing and first patient dose expected in H2 2023

## Summary
- FDA provided guidance on the proposed program for briquilimab for chronic spontaneous urticaria (CSU).
- Company expects to file IND for briquilimab in CSU and dose first patient in H2 2023.
- Jasper will continue engagement with FDA toward IND submission and launch of CSU clinical trial.
- Updated corporate presentation posted on company website as of June 2, 2023.

## SEC filing metadata
- accession: 0001213900-23-045834
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2023-06-02T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390023045834/0001213900-23-045834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390023045834/ea179684-8k_jasperthera.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-045834
- JSON: https://secwatch.observer/filing/0001213900-23-045834.json
- Plain text: https://secwatch.observer/filing/0001213900-23-045834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.